NICE National Institute for Health and Care Excellence

Single Technology Appraisal

Bortezomib for previously untreated mantle cell lymphoma

Committee Papers

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

SINGLE TECHNOLOGY APPRAISAL

Bortezomib for previously untreated mantle cell lymphoma

Contents:

1. **Pre-Meeting Briefing**

2. **Final Scope and Final Matrix of Consultees and Commentators**

3. **Company submission** from **Janssen**

4. **Clarification letters**
   - NICE request to the company for clarification on their submission
   - Company response to NICE's request for clarification

5. **Patient group, professional group and NHS organisation submission** from:
   - Leukaemia CARE
   - Royal College of Pathologists
   - Royal College of Physicians

6. **Expert statements** from:
   - Professor Simon Rule, Consultant Haematologist / Professor of Clinical Haematology, nominated by Janssen and Royal College of Physicians – clinical expert
   - Ms Katharine Robinson, nominated by Lymphoma Association – patient expert

7. **Evidence Review Group report** prepared by Kleijnen Systematic Reviews

8. **Evidence Review Group report - post pre meeting briefing**

9. **Evidence Review Group report – factual accuracy check**

Any information supplied to NICE which has been marked as confidential, has been redacted. All personal information has also been redacted.